Pembrolizumab-induced agranulocytosis.

Introduction: With the widespread use of anti-programmed death-1 monoclonal antibodies, such as pembrolizumab, rare side effects appear in clinical practice.

Case Report: We report the case of a man diagnosed with non-keratinizing squamous lung carcinoma stage IVB with programmed death-ligand 1 70% who developed agranulocytosis 10 days after a single dose of pembrolizumab as monotherapy.

Management And Outcome: Pembrolizumab was discontinued immediately.